New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 14, 2014
08:04 EDTNKTRNektar announces dosing of first subject in Phase 1 study for NKTR-171
Nektar Therapeutics announced that the first subjects were dosed in a Phase 1 clinical study for NKTR-171, a new sodium channel blocker being developed as an oral therapy for the treatment of peripheral neuropathic pain.
News For NKTR From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
March 24, 2015
10:17 EDTNKTROptions with decreasing implied volatility
Options with decreasing implied volatility: FOLD NKTR GES VHC CTRP WSM WLL LNCO NLY ORCL
March 23, 2015
11:22 EDTNKTROptions with decreasing implied volatility
Options with decreasing implied volatility: FOLD NKTR RUSL XONE GES CTRP WSM NLY ADBE ORCL
March 20, 2015
10:18 EDTNKTROptions with decreasing implied volatility
Options with decreasing implied volatility: NKTR FOLD RUSL RSX ORCL GES CTRP SLXP WSM SPXS
March 19, 2015
10:42 EDTNKTROptions with decreasing implied volatility
Subscribe for More Information
08:37 EDTNKTRNektar and Daiichi Sankyo to commercialize Movantik in the U.S.
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use